Trials / Not Yet Recruiting
Not Yet RecruitingNCT07279532
Clinical Study of Adjuvant Surufatinib Therapy for Postoperative High-risk Neuroendocrine Tumors Based on the Ninth Edition of the AJCC Staging System
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 35 (estimated)
- Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The following issues warrant in-depth investigation: further refinement of staging by primary tumor site, the increasing prognostic weight of T classification, risk assessment for lymph node metastasis and postoperative recurrence/distant metastasis, and whether NET G3 with poor prognosis requires more aggressive postoperative intervention. This study plans to enroll patients classified as Stage III according to the AJCC 9th Edition staging system, including NET G1/G2 and all G3 patients, for a clinical trial on postoperative adjuvant therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | surufatinib | Surufatinib 200mg, administered orally once daily (QD), for 6 months as postoperative adjuvant therapy. |
Timeline
- Start date
- 2026-01-01
- Primary completion
- 2029-12-31
- Completion
- 2030-12-31
- First posted
- 2025-12-12
- Last updated
- 2025-12-12
Source: ClinicalTrials.gov record NCT07279532. Inclusion in this directory is not an endorsement.